Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $15.50

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $15.50.

A number of research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $17.00 target price on shares of NeuroPace in a research report on Wednesday, May 14th. JPMorgan Chase & Co. raised their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 14th. Finally, HC Wainwright started coverage on shares of NeuroPace in a report on Wednesday, May 28th. They issued a “buy” rating and a $18.00 price objective for the company.

NeuroPace Trading Up 1.8%

NPCE opened at $10.76 on Friday. The company has a debt-to-equity ratio of 2.46, a current ratio of 6.63 and a quick ratio of 5.70. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.98. The firm has a market capitalization of $352.92 million, a PE ratio of -12.81 and a beta of 2.03. The company’s 50-day moving average is $12.83 and its 200 day moving average is $12.37.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. The firm had revenue of $22.52 million during the quarter, compared to analyst estimates of $21.85 million. NeuroPace had a negative net margin of 29.42% and a negative return on equity of 190.84%. As a group, research analysts predict that NeuroPace will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the firm’s stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the transaction, the insider now directly owns 3,238,199 shares of the company’s stock, valued at $51,325,454.15. This trade represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 20.50% of the company’s stock.

Institutional Trading of NeuroPace

Institutional investors and hedge funds have recently made changes to their positions in the stock. Northern Trust Corp raised its position in NeuroPace by 15.7% in the 4th quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock worth $2,068,000 after purchasing an additional 25,035 shares during the period. Two Sigma Investments LP purchased a new position in NeuroPace in the 4th quarter worth $293,000. JPMorgan Chase & Co. raised its position in NeuroPace by 440.4% in the 4th quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock worth $725,000 after purchasing an additional 52,829 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in NeuroPace in the 4th quarter worth $639,000. Finally, Point72 Asset Management L.P. purchased a new position in NeuroPace in the 4th quarter worth $369,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.